drugset / Trial / NCT00685711
Safety of Cat-PAD in Cat Allergic Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. Cat-PAD is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of cat allergy. This study will investigate the safety of Cat-PAD administered as increasing single doses.
Timeline
- Start
- 2008-01
- Primary completion
- 2008-07
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cat-PAD | Peptide | 0.03 unknown | — |
| Subject | Cat-PAD | Peptide | 0.3 unknown | — |
| Subject | Cat-PAD | Peptide | 3 unknown | — |
| Subject | Cat-PAD | Peptide | 12 unknown | — |
| Subject | Cat-PAD | Peptide | 20 unknown | — |
Indications
No indication recorded.